Nevertheless, based on the detrimental effect of AIM2 activation in the establishment and progression of certain types of cancer, and on the proved anticancer activity of calixarene-based compounds [112], it is possible to hypothesize the use of 4-sulfonic calixarenes as an effective inhibitor of the AIM2 inflammasome, pointing at future translational opportunities to target AIM2 in cancer patients. The gene discussed is AIM2; the disease is cancer.